non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Ikeda Norihiko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients 18 years of age or older at the time of written consent. 2) Patients with PD-L1 positive non-small cell lung cancer who had received complete resection and are scheduled to receive atezolizumab adjuvant therapy in clinical practice, based on the atezolizumab package insert and the Optimal Use Promotion Guideline. 3) Patients who had received appropriate explanation about the study and was willing to give written consent.
Exclusion criteria
Exclusion criteria: 1) Patients who are unsuitable for enrolment into the study by the investigator's judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year disease-free survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) DFS (2) Disease-free survival rate (3) OS (4) Recurrence site (5) Incidence rate of Adverse Events (6) irAE incidence rate (7) the following items for subgroup analysis 1) sex 2) age at the time of consent 3) ECOG PS 4) smoking history 5) histological type 6) preoperative clinical stage and postoperative pathological stage 7) prescribed regimen of postoperative adjuvant chemotherapy 8) administrated cycle number of postoperative adjuvant chemotherapy 9) completion or discontinuation of Atezolizumab treatment 10) PD-L1 status 11) with or without irAE onset 12) driver mutation 13) Other by patient background | — |
Contacts
Public ContactStudy coordinating center J-CURE
EPS Corporation
Outcome results
None listed